Name of this trial: TRIDENT
What type of cancer is this for? Pancreatic Adenocarcinoma
Who is this trial for? Subjects With Previously Untreated Metastatic Pancreatic Adenocarcinoma
What biomarkers are involved? N/A
What is the National Clinical Trial #? NCT07259317; https://clinicaltrials.gov/study/NCT07259317
Brief summary of this trial: Phase 2, single arm trial of Relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma
Need to know: Must have histologic diagnosis or cytologic diagnosis of pancreatic adenocarcinoma (PDAC); initial diagnosis of metastatic disease occurred ≤6 weeks prior to enrollment in the study. Must not have received prior systemic anticancer therapy to treat metastatic disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: MountainTap-30
What type of cancer is this for? Pancreatic Cancer
Who is this trial for? Patients with treatment naïve metastatic pancreatic cancer
What biomarkers are involved? MTAP deletion
What is the National Clinical Trial #? NCT07076121 https://clinicaltrials.gov/study/NCT07076121?term=NCT07076121&rank=1
Brief summary of this trial: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Need to know: Patients must not have received any treatment in the metastatic setting. Must have MTAP deletion which will be verified through central testing.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]